Способ инициации гибели опухолевых клеток натриевыми солями хлорина-e, хлорина-pи пурпурина-5 и ВЧ- и СВЧ-энергией волнового излучения

Изобретение относится к медицине и предназначено для индукции гибели опухолевых клеток в живых биологических объектах с использованием растворов натриевых солей хлорина-е, хлорина-ри пурпурина-5 препарата "Радахлорин" электромагнитной ВЧ- и СВЧ-энергией фотоволнового излучения, известного как ВЧ- и СВЧ-гипертермия. Описан способ инициации гибели опухолевых клеток, предназначенный для комплексного лечения онкологических больных, имеющих опухолевые ткани с метастазами для их гипертермии в органах организма человека, характеризующийся тем, что до лечения человек в течение 3 дней переводится на безуглеводную диету, для создания глюкозного голодания и последующего максимального насыщения онкоклеток электронно-ионным раствором натриевых солей хлорина-е, хлорина-ри пурпурина-5 препарата "Радахлорин" при внутривенном введении в мегадозе 2,5 мг/кг веса человека при его накоплении в 3-4 раза выше, чем в здоровых, и через 5 часов после введения препарата "Радахлорин" проводится избирательная гипертермия ...

КОМПЛЕКС ГАРЦИНОЛА И ЦИКЛОДЕКСТРИНА И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Изобретение относится к комплексу гарцинола и циклодекстрина, применяемому для регулирования и лечения состояний сердечной дисфункции. Указанный комплекс включает гарцинол и циклодекстрин в молярном соотношении от 1:1 до 1:4,5. Также изобретение относится к способу получения указанного комплекса, композициям, содержащим указанный комплекс, и способу регулирования и лечения состояний сердечной дисфункции, включающему введение фармацевтически эффективного количества указанного комплекса. Изобретение характеризуется высокой эффективностью и низкой токсичностью при лечении различных состояний сердечной дисфункции. 5 н. и 18 з.п. ф-лы, 3 ил., 20 табл., 14 пр.

СОЕДИНЕНИЕ КЕТОНА ИЛИ ОКСИМА И ГЕРБИЦИД

Настоящее изобретение относится к соединению оксима или его соли формулы (1), которое может быть использовано в качестве гербицида:,где B представляет собой кольцо из любого одного из B-1-а или B-2-а; Q представляет собой =NOR; а R, R, R, R, R, R-R, A, Z, Z, Z, m, n имеют значения, указанные в формуле изобретения. 2 н. и 1 з.п. ф-лы, 26 табл., 23 пр.

ПИПЕРАЗИНИЛ- И ПИПЕРИДИНИЛЦИКЛОГЕКСАНОЛЫ И ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ПОВЫШЕНИЯ СЕРОТОНИНЕРГИЧЕСКОЙ НЕЙРОТРАНСМИССИИ

Пиперазинил- и пеперидинилциклогексанолы общей формулы: и их фармацевтически приемлемые соли, где R1 и R2 - H, галоген, CF3, C1-C4-алкокси, причем R1 и R2 не могут одновременно означать H, и R1 и R2, если они находятся у соседних атомов углерода, могут образовывать вместе мостик -0-(CH2)n-0-, где n - целое число от 1 до 3; R3 - H, C1-C4-алкил; R4 и R5 - H, C1-C4-алкил или фенил; Y - N или CH; Ar - фенил, 2-тиенил или замещенный фенил формулы - (C6H4)XpX 1 q , где заместители X и X1 - галоген, нитро, C1-C4-алкил, C1-C4-алкокси и X и X1 вместе образуют мостик -0-(CH2)n, где n - целое число от 1 до 3; p и q целые числа от 0 до 5, причем p + q≅5; раскрыты фармацевтическая композиция, обладающая активностью связывать серотонинергический 5-HTIA рецептор, содержащая вещество формулы I, и способ лечения серотонинергической нейтротрансмиссии путем введения соединения I. 3 с. и 14 з.п. ф-лы.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОИЗВОДНОЕ ВЕРБЕНОЛА, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕЙРОДЕГЕНЕРАТИВНОГО ЗАБОЛЕВАНИЯ

... 1. Фармацевтическая композиция для профилактики или лечения дегенеративного заболевания мозга, содержащая в качестве действующего вещества производное вербенона, представленное изображенной ниже формулой 1, или его фармацевтически приемлемую соль:где R, R, R, Rи Rкаждый независимо представляют собой по меньшей мере один заместитель, выбранный из группы, состоящей из атома водорода, атома галогена, выбранного из F, О, Br и I, гидроксильной группы, С-Салкильной группы, С-Салкокси-группы, амино-группы, С-Салкиламино-группы, С-Салкилдиамино-группы, С-Сароматического цикла, C-Cциклического кольца и C-Cгетероароматического цикла;X, Y и Z каждый независимо представляют собой атом углерода или по меньшей мере один гетероатом, выбранный из группы, состоящей из атомов N, О S; иозначает двойную связь или одинарную связь.2. Фармацевтическая композиция по п. 1, в которой R, R, R, Rи Rкаждый независимо представляют собой по меньшей мере один заместитель, выбранный из группы, состоящей из атома водорода ...

Способ получения производных 3-(2-гидрокси-4-замещенных фенил)циклоалканола

Изобретение касается замещенных циклоалифатических спиртов, в частности получения производных -гидрокси-4- ( замещенных I , - Диметил гептил или 1 метилгептилокси)--фенил- С С циклоалканола , имеющего гидроксипропил кпи 4 гидроксибутил, или З петоксипропил, которые прояв ляют анальгетическое действие и мо гут быть использованы в медицине. Цель изобретения создание актив ных и малотоксичных веществ указанного класса. Их синтез ведут восстано влением соответствующего диклоалка нона, замещенного фенилбензильной группой, с последующим дебензилирова- нием полученного продукта. Испытания новых веществ показывают противорвот- ное действие без побочных токсичных действий, а также анальгетическое . действие против болевых: и химических раздражителей. 8 табл. § С ...

Способ получения производных 4-/2-окси-4-замещенных/ фенилнафталин-2-олов

Способ получения производных 1-оксо-5-инданилоксиуксусной кислоты

NEUE BENZYLIDENCYCLANON-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS ANTIOXIDATIONSMITTEL UND ALS SONNENFILTER SOWIE KOSMETISCHE UND PHARMAZEUTISCHE MITTEL, DIE DIESE DERIVATE ENTHALTEN

Benzylidenecyclanone compounds of formula: [in which: R1 and R are independently hydrogen, hydroxyl, C1-C8 alkyl or C1-C8 alkoxy (with the reservation that at least one of the radicals R1 and R is other than hydrogen); R2 and R3 are independently hydrogen or hydroxyl (with the reservation that at least one of the radicals R2 and R3 is hydroxyl); R4, R5, R6 and R7 are independently C1-C18 alkyl, aralkyl (optionally substituted by C1-C4 alkyl or C1-C4 alkoxy), aryl (optionally substituted by C1-C4 alkyl); or the substituents R4 and R5 and/or the substituents R6 and R7 form, together with the carbon atom of the ring to which they are attached, a saturated ring containing from 5 to 12 carbon atoms which is optionally substituted by one or more C1-C8 alkyl(s); and X is CH2, (CH2)2 or N-R8 (in which R8 is hydrogen, C1-C8 alkyl, aralkyl (optionally substituted by C1-C4 alkyl or C1-C4 alkoxy), hydroxyl or C1-C8 alkoxy) or alternatively X is oxygen or sulphur] have anti-oxidant and wide-band ...

OXIMINAETHERDERIVATE.

1,2-1,4-Additions-Reaktionsschritt, der zu Diphenylacetylenen führt.

Glyoxyl-Cyclohexendione.

VERFAHREN ZUR HERSTELLUNG NEUER BICYCLISCHER VERBINDUNGEN

VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN TETRALINEN, CHROMANEN UND VERWANDTEN VERBINDUNGEN, DIE BEI DER BEHANDLUNG VON ASTHMA VERWENDET WERDEN KOENNEN

2-ARYLCYCLOPENTAN-1,3-DIONE

SUBSTITUTED INDONAPHTHOLS USED IN DETECTING IONS

DIARYLINDANE-1,3-DIONES, THEIR PREPARATION AND USE

Cyclopentan-1,3-dion-Derivate

The invention concerns novel bicyclic cyclopentane-1,3-dione derivatives of formula (I), in which A, B, B', G, Q, X, Y and Z have the meanings indicated in the description, a method of producing said derivatives and their use as pest-control agents and herbicides.

Pesticidal oximes

A compound of formula I I in which formula: Ra represents hydrogen or a C1-C6 alkyl group, and Rc represents a C1-C6 alkyl group; Rb represents a phenyl group, optionally substituted by a C1-C6 alkyl group or halogen, a group of formula -CH=CRdRe in which Rd and Re, which may be identical or different represent hydrogen or C1-C6 alkyl groups or a group of formula -CH=NORf in which Rf represents hydrogen or a C1-C6 alkyl group and RCOO represents a residue of an acid RCO2H, which acid, or an ester-forming derivative of which acid, on reaction with alpha -cyano-3-phenoxybenzyl alcohol or an ester forming derivative thereof, gives rise to an alpha -cyano-3-phenoxybenzyl ester having pesticidal properties.

Substituted octalinones and tetrahydro-indanones of use as intermediates in steroid synthesis

... 975,594. Substituted octalinones and tetrahydroindanones. H. SMITH. Dec. 20, 1960 [Sept. 25, 1959(2); Feb. 19, 1960], Nos. 40557/60, 40558/60 and 40559/60. Divided out of 975,593. Heading C2C. The invention comprises compounds of formula wherein Ar is phenyl which may be substituted in the m-position with hydroxy, alkoxy, acyloxy, nitro, amino, acylamino or alkylamino as sole substituent, each R is H or alkyl, R 1 is alkyl, Q is methylene or ethylene, and Y is carbonyl, ketalised carbonyl, hydroxymethylene or acyloxymethylene. The compounds and those in which Ar is more generally phenyl having an unsubstituted ortho-position may be prepared by one of the following methods: (a) (Y=carbonyl) cyclodehydration of a compound of formula (b) (Y=carbonyl) condensation of a compound ArCR 2 CR 2 X (X=Cl, Br or organic sulphonyloxy) with a metal enolate of a ketone of structure. (c) (Y=hydroxymethylene) selective reduction of the corresponding compound wherein Y is carbonyl and (d) (Y=ketalised ...

Herbicidal hydroxylimino cyclohexane-1,3-dione derivatives

The invention concerns novel compounds of the formula I I wherein R1 is selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, acyl, alkylsulfonyl, benzenesulfonyl, substituted benzenesulfonyl, and an inorganic or organic cation; R2 is selected from alkyl, alkenyl, alkynyl, substituted alkyl, haloalkenyl and haloalkynyl; R3 is selected from alkyl, fluoroalkyl, alkenyl, alkynyl and phenyl; and n is an integer chosen from 2 to 5. The compounds are cereal selective herbicides and in further embodiments of the invention provides processes for the preparation of compounds of formula I, intermediates useful in the preparation of compounds of formula I, herbicidal compositions containing as active ingredient a compound of formula I, and processes for severely damaging or killing unwanted plants by applying to the plants or to the growth medium of the plants an effective amount of a compound of formula I.

PESTICIDES

TETRAHYDRONAPHTHALINE & INDANE DERIVATIVES

SUBSTITUTED TETRARINS CHROMANS & RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA,ARTHRITIS ETC.

Substituted tetralins, chromans and related compounds in the treatment of asthma, arthtitits and related diseases.

Substituted tetralins, chromans and related compounds ...

Glucocorticoid receptor modulators.

The present invention provides non-steroidal compounds of formula (I) which are selective modulators (i.e. agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for the preparing these compounds.

Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same.

The subject of the invention is the products of formula (I) : in which R-1, R2, R3 / £4,R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.

Novel herbicides.

4-phenylpyrane-3,5-diones,4-phenylthiopyrane-3,5-diones and 2-phenylcyclohexane-1,3,5-triones as herbicides

Herbicidally active bicyclic 1,3-dione compounds

INHIBITORS OF BETA-SECRETASE

Tric clic ompou ds ha ing a tivity specific for integrins particularly avbs intergrins method for preparing same intermediates therefore use of said compounds as drugs and pharmaceutical compositions containing same

Glucocorticoid receptor modulators

4-phenyl-pyrane-3,5-diones, 4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones as novel herbicides

Herbicidally active bicyclic 1,3-dione compounds

Inhibitors of beta-secretase

Inhibitors of beta-secretase

Oximino ether compounds

Glucocorticoid receptor modulators.

Tricyclic compounds having an activity screw-with-visdes intégrines in particular with respect to the intégrine ALPHAvBETA3, their method of preparation and I ntermédiaires of this process, their application as drugs and the compositions pharmaceutical containing them.

Oximino ether compounds.

Composed of 2-aryl-1,3-cyclohexane, their ammonium and metal salts alkaline, their derivatives esters enolic and their preparation.

Process of production of substituted tetralin derivatives, chromanes and compounds related.

Inhibitors of beta-secretase

4-phenylpyrane-3,5-diones,4-phenylthiopyrane-3,5-diones and 2-phenylcyclohexane-1,3,5-triones as herbicides

Herbicidally active bicyclic 1,3-dione compounds

Inhibitors of beta-secretase

Inhibitors of beta-secretase

Tric clic ompou ds ha ing a tivity specific for integrins particularly avbs intergrins method for preparing same intermediates therefore use of said compounds as drugs and pharmaceutical compositions containing same

SUBSTITUTED TETRARINS CHROMANS & RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA,ARTHRITIS ETC.

Glucocorticoid receptor modulators

Glucocorticoid receptor modulators

Inhibitors of beta-secretase

4-phenyl-pyrane-3,5-diones, 4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones as novel herbicides

Herbicidally active bicyclic 1,3-dione compounds

Novel herbicides.

4-phenylpyrane-3,5-diones,4-phenylthiopyrane-3,5-diones and 2-phenylcyclohexane-1,3,5-triones as herbicides

VERFAHREN ZUR HERSTELLUNG VON NEUEN PHENAN- THRENEN

PROCEDURE FOR THE PRODUCTION OF NEW PHENAN THRENEN

NEW ONE TETRAHYDRONAPHTHALIN AND INDANDERIVATE

4-ARYL SUBSTITUTED CHINOLE AND ANALOGUES AS THERAPEUTIC ACTIVE SUBSTANCES

PHENYL BENZYLE KETONE

C2-PHENYLSUBSTITUIERTE CYCLI KETOENOLE AS PESTICIDES AND HERBICIDES

INITIATORS FOR THE PHOTO POLYMERIZATION

PROCEDURE FOR the PRODUCTION of NEW, FOR the TREATMENT OF PSORIASIS SERVING 1,8-DIHYDROXY-10-ACYL-9 - ANTHRONES

PROCEDURES FOR THE PRODUCTION OF NEW ONE, BASIC SUBSTITUTED INDANDERIVATEN

PROCEDURE FOR the PRODUCTION of a NEW OPTICAL ISOMER of a 1-HYDROXY-3-SUBSTITUIERTEN-6,6 DIMETHYL-6,6A, 7,8,10,10A-HEXAHYDRO-9H-DIBENZO (B, D) PYRAN -9-ONS

ILLUDIN MORE SIMILARLY, USES AS ANTI-TUMOR MEANS

8 (NIEDERALKYL) BICYCLO (4.2.0>OCTANDERIVATE WITH VALUABLE THERAPEUTIC CHARACTERISTICS.

MORE ARYLARALKYLETHER, PROCEDURES FOR THEIR PRODUCTION AND THIS CONTAINING PHARMACEUTICAL COMPOSITION.

(ETHYLENEDIOXO-3,3 ZYCLOHEXYL) - 4 AKETOPHENON AND DERIVATIVES OF IT, PROCEDURES FOR THEIR PRODUCTION AND USE OF THESE CONNECTIONS.

SUBSTITUTED TETRALINE, CHROMANE AND RELATED CONNECTIONS FOR THE TREATMENT OF ASTHMA, ARTHRITIS AND USED DISEASES.

NEW ONE TETRAHYDRONAPHTHALIN AND INDANDERIVATE

OXIMINO ETHER CONNECTIONS.

FLUORNAPHTHACENDIONE, OF THEM GLYCOSILIERTE DESCENDANTS AND PROCEDURES FOR THEIR PRODUCTION.

GLYOXYL CYCLOHEXENDIONE ONE.

SUBSTITUTED (5,6) - DIHYDRONAPHTHALINYLVERBINDUNGEN WITH RETINOID WELL-BEHAVED EFFECT

USE OF PERMANENT FREE RADICALS RESONANCE MAGNETIC FOR THE IMAGING OF MEANS

SUBSTITUTED INDONAPHTHOLE AND THEIR USE FOR PROVING IONS.

(3.2.0) BICYCLOHEPTANON MORE OXIMAETHER, THE VALUABLE THERAPEUTIC CHARACTERISTICS POSSESSIONS.

PROCEDURE FOR THE PRODUCTION OF NICHTSTEROIDALE GLUCOCORTICOIDREZEPTOR MODULATORS

NEW HERBICIDES

ESTROGENREZEPTORLIGANDEN AND PROCEEDING

PROCEDURES FOR THE PRODUCTION OF NEW ONE, BASIC SUBSTITUTED INDANDERIVATEN

PROCEDURE FOR the PRODUCTION OF NEW ONE 6,7-DICHLOR-1-INDANONVERBINDUNGEN

ISOFLAVON METABOLITE

PROCEDURE FOR the PRODUCTION OF NEW ONE 11-AMINO-BENZO (B) BICYCLO (3,3,1) NONA-3,6A (10A) SERVING AND THEIR SOUR ADDITION SALTS

CYCLI UREA AND ANALOGUES USABLE AS RETROVIRALE OF PROTEASEHEMMER

INHIBITION OF INSATIATED MONOMERS WITH 7 ARYLCHINONMETHIDEN

HYDRAZONO BENZAZULEN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE PRODUCTS

BIZYKLI CARBON ACID LEUKOTRIEN B4 ANTAGONIST

Inzektizides and akarizides means

SUBSTITUTED TETRA OR HEXAHYDRONAPTHALENONES AND DIONES

6-STYRYL-TETRAHYDRONAPHTHALENES & 5-STYRYL-INDANES

4- 2-HYDROXYPHENYL PERHYDRONAPTHALEN-2-OLS AND DERIVATIVES

NUCLEAR HORMONE RECEPTOR COMPOUNDS, PRODUCTS AND METHODS EMPLOYING SAME

GENES FOR BIOSYNTHESIS OF TETRACYCLINE COMPOUNDS AND USES THEREOF

The invention relates to tetracycline products produced by genetically engineered cells, and to therapeutic methods using such tetracyclines. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway. 3. Use of a compound of for the treatment of bacterial or fungal infections claim 1 , treatment of malaria claim 1 , a neurodegenerative disease claim 1 , Parkinson's disease claim 1 , Huntington's claim 1 , disease claim 1 , periodontitis claim 1 , an autoimmune condition claim 1 , multiple sclerosis claim 1 , atherosclerosis claim 1 , rheumatoid arthritis claim 1 , osteoporosis claim 1 , tumour invasion claim 1 , cancer and inflammatory states.4. Use of a compound of for the treatment of bacterial or fungal infections.5. Use of a compound of for the treatment of bacterial or fungal infections claim 2 , treatment of malaria claim 2 , a neurodegenerative disease claim 2 , Parkinson's disease claim 2 , Huntington's claim 2 , disease claim 2 , periodontitis claim 2 , an autoimmune condition claim 2 , multiple sclerosis claim 2 , atherosclerosis claim 2 , rheumatoid arthritis claim 2 , osteoporosis claim 2 , tumour invasion claim 2 , cancer and inflammatory states.6. Use of a compound of for the treatment of bacterial or fungal infections. This application is a divisional of U.S. patent application Ser. No. 12/536,622 filed Aug. 6, 2009, now U.S. Pat. No. 8,361,777, which claims the benefit of EP Application No. 08014141.9 filed Aug. 7, 2008, the entire disclosures of which are incorporated herein by reference.This invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.Tetracyclines are a large group of drugs with a ...

SHIP1 MODULATORS AND RELATED METHODS

Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, Rand A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed. 19. A composition comprising a compound of in combination with a pharmaceutically acceptable carrier or diluent.20. A method for modulating SHIP1 comprising administering an effective amount of a composition of to an animal in need thereof.21. A method for treating a disease claim 19 , disorder or condition comprising administering an effective amount of a composition of to an animal in need thereof claim 19 , where the disease claim 19 , disorder or condition is an autoimmune disease claim 19 , disorder or condition claim 19 , an inflammatory disease claim 19 , disorder or condition claim 19 , or a neoplastic or cell proliferative disease claim 19 , disorder or condition.22. The method of wherein the disease claim 21 , disorder or condition is an autoimmune disease claim 21 , disorder or condition selected from idiopathic pulmonary fibrosis claim 21 , an inflammatory bowel disease claim 21 , rheumatoid arthritis claim 21 , Still's Disease claim 21 , Sjögren's Syndrome claim 21 , systemic lupus erythematosus claim 21 , and systemic sclerosis.23. The method of claim 22 , wherein the disease claim 22 , disorder or condition is an inflammatory bowel disease selected from Crohn's Disease and ulcerative colitis.24. The method of wherein the disease claim 21 , disorder or condition is an inflammatory disease ...

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. 2. A compound according to or a pharmaceutically acceptable salt thereof for use as a medicament.3. A pharmaceutical composition comprising at least one compound according to or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant claim 1 , diluent and/or carrier.4. A compound according to or a pharmaceutically acceptable salt thereof for use in the treatment of a BACE1 mediated disorder or disease.5. A compound or a pharmaceutically acceptable salt thereof for use according to claim 4 , wherein the BACE1 mediated disorder or disease is selected from the group consisting of a neurodegenerative disorder claim 4 , cognitive decline claim 4 , cognitive impairment claim 4 , dementia claim 4 , and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.6. A compound or a pharmaceutically acceptable salt thereof for use according to claim 5 , wherein the disorder or disease is selected from the group consisting of Alzheimer's disease claim 5 , Trisomy 21 (Down Syndrome) claim 5 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D) claim 5 , senile dementia claim 5 , cerebral amyloid angiopathy claim 5 , degenerative dementia claim 5 , dementias of mixed vascular and degenerative origin claim 5 , dementia associated with Parkinson's disease claim 5 , dementia associated with progressive supranuclear palsy claim 5 , dementia associated with cortical basal degeneration claim 5 , diffuse Lewy body type of Alzheimer's disease claim 5 , dry age related ...

SYNTHESIS OF RESVERATROL-BASED COMPOUNDS

A compound having the structure: This application claims priority of U.S. Provisional Application No. 61/400,111, filed Jul. 21, 2010, the contents of which are hereby incorporated by reference.Throughout this application, various publications are referenced by citation in parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.The past decade has witnessed tremendous interest in the relatively small natural product resveratrol (1, ) based primarily on its possession of a promising and selective array of in vitro and in viva activity against a collection of disease states, including inflammation, heart disease, aging, and cancer [1]. In fact, its truly unique biochemical profile, coupled with its relatively high concentration in red wine (˜100 mM) and near absence in white varietals and grape juice, has led to the popularly held notion that resveratrol is the main protagonist for the so-called “French paradox” [2]. Amazingly, however, virtually no effort has been devoted to the large family of resveratrol-based oligomers (such as 2-8) [3] produced combinatorially by plants throughout the world in response to environmental stress, compounds which initial screening suggest should have unique, if not superior, activity profiles to resveratrol itself [4].In one embodiment, this invention provides a compound having the structureThis invention provides a compound having the structureIn some embodiments, the invention includes the compound wherein in the compound each occurrence of Ris independently H, CH, C(O)CH, P(O)(OR), SOOR, SOR, or C(O)R,In some embodiments, the invention includes the compound wherein in the compoundIn some embodiments, the invention includes the compoundwherein the structure isor a salt thereof.In some embodiments, the invention ...

COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME

In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same. 4. (canceled)611.-. (canceled)12. The compound of claim 1 , wherein the compound is isolated from a plant in the Salviniaceae family.13Salvinia. The compound of claim 12 , wherein the compound is isolated from a plant in the genus.14S. auriculata, S. biloba, S. cucullata, S. cyathiformis, S. hastate, S. herzogii, S. minima, S. molesta, S. natans, S. nymphellula, S. oblongifolia, S. radula, S. rotundifoliaS. sprucei.. The compound of claim 12 , wherein the compound is isolated from claim 12 , or15Azolla. The compound of claim 12 , wherein the compound is isolated from a plant in the genus.16. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) the compound according to or a pharmaceutically acceptable salt thereof; and'}(b) an excipient.17. A method of treating cancer in a patient in need thereof claim 1 , comprising administering to the patient a pharmaceutical composition comprising a compound according to in an amount sufficient to treat the cancer.18. The method of claim 17 , wherein the cancer is melanoma claim 17 , cervical cancer claim 17 , breast cancer claim 17 , ovarian cancer claim 17 , prostate cancer claim 17 , testicular cancer claim 17 , urothelial carcinoma claim 17 , bladder cancer claim 17 , non-small cell lung cancer claim 17 , small cell lung cancer claim 17 , sarcoma claim 17 , colorectal adenocarcinoma claim 17 , gastrointestinal stromal tumors claim 17 , gastroesophageal carcinoma claim 17 , colorectal cancer claim 17 , pancreatic cancer claim 17 , kidney cancer claim 17 , hepatocellular cancer claim 17 , malignant mesothelioma claim 17 , leukemia claim 17 , lymphoma claim 17 , myelodysplastic syndrome claim 17 , multiple myeloma claim 17 , transitional cell carcinoma claim 17 , neuroblastoma claim 17 , ...

Cosmetic Composition Comprising Vetiver Root Extract

A cosmetic composition is provided, which comprises a carrier and a Vetiver root extract, in particular an extract from exhausted Vetiver root. This composition provides a stimulation of sebum production, stimulation of sebum antimicrobial, lipids production, activation of adipocytes volume increase, skin hydration, skin tonicity booster, skin fatigue reduction, perilabial wrinkles reduction, skin replumping, and fragrance long-lastingness enhancement. 1. A cosmetic composition comprising a carrier and at least one active cosmetic ingredient , wherein the at least one active cosmetic ingredient comprises a Vetiver root extract.2. The cosmetic composition according to claim 1 , wherein the cosmetic composition is a skin care composition.3. The cosmetic composition according to claim 1 , wherein the at least one active cosmetic ingredient comprises an aqueous extract of Vetiver root.4. The cosmetic composition according to claim 1 , wherein the at least one active cosmetic ingredient comprises an extract of exhausted Vetiver root.5. A method of preparing an active cosmetic ingredient claim 1 , comprising the step of: extracting Vetiver root.6. The method according to claim 5 , comprising the steps of:(i) providing exhausted Vetiver root; and(ii) extracting the exhausted Vetiver root.7. The method according to claim 5 , wherein the extraction is performed using water.8. (canceled)9. A method of stimulating the sebum production claim 1 , of stimulating sebum antimicrobials claim 1 , of stimulating the lipids production claim 1 , of activating the adipocytes volume increase claim 1 , of improving the skin hydration claim 1 , of boosting the skin tonicity claim 1 , of reducing skin fatigue claim 1 , of reducing perilabial wrinkles claim 1 , of replumping skin claim 1 , and/or of enhancing fragrance long-lastingness claim 1 , the method comprising the step of: applying the cosmetic composition of to human skin. The present invention relates to cosmetic compositions ...

1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media. 3. The 1 claim 1 ,3-Dioxoindene derivatives claim 1 , pharmaceutically-acceptable salt thereof or optical isomer thereof as set forth in claim 1 , wherein claim 1 , A claim 1 , A claim 1 , Aand Aare claim 1 , either independently or optionally claim 1 , any one selected from a group consisting of —H claim 1 , halogen and —NRR;{'sup': 1', '2', '1', '2, 'G is —OH, —NR(C═O)Ror —NR(C═O)OR;'}{'sup': 1', '2', '3', '4', '1', '2, 'sub': 1', '10, 'D, D, Dand Dare, either independently or optionally, any one selected from a group consisting of halogen, C˜Cstraight- or side-chain alkyl and —NR(C═O)R;'}{'sup': 1', '1', '1', '1', '2, 'E is —H, —OH, —OR, —O(C═O)R, —O(C═O)ORor —O(C═O)NRR;'}{'sup': 1', '2', '3, 'sub': 1', '8', '1', '4', '6', '10, 'R, Rand Rare, each independently, hydrogen, nonsubstituted or phenyl-substituted C˜Cstraight- or side-chain alkyl, nonsubstituted or phenyl-substituted C˜Cstraight- or side-chain alkenyl or C˜Caryl;'}X and Y are oxygen;{'sup': 1', '2', '3, 'Z, Zand Zare carbon;'}n is integer between 1˜3; and{'img': {'@id': 'CUSTOM- ...

INHIBITION OF DYRK1A KINASE

Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each six-membered ring includes at least one oxygen-bearing substituent selected from carbonyl oxygens, hydroxyls, alkoxyls, and halogenated derivatives thereof. The compounds can be administered to mammalian subjects for inhibition of DYRK1A kinase proteins. 2. The one or more compounds of claim 1 , wherein at least one of R2 or R4 in compound I is a methyl group claim 1 , or wherein at least one R2′ or R4′ in compound II is a methyl group.3. The one or more compounds of claim 1 , where the linker -[ ]-is a methylene bridge.4. The one or more compounds of claim 1 , at least one of R2 or R1 in compound I is an isopropyl group claim 1 , or wherein at least one R1′ or R2′ in compound II is an isopropyl group.7. The one or more compounds of claim 1 , said compounds selected from the group consisting of the isomers claim 1 , tautomers claim 1 , esters claim 1 , metal complexes claim 1 , and salts of the structures.8. A composition comprising a plurality of one or more compounds of dispersed in a carrier.9. The composition of claim 8 , comprising a plurality of compounds according to structure I and a plurality of compounds according to structure II dispersed in said carrier.10. A method of inhibiting DYRK1A activity comprising the step of contacting DYRK1A kinase with an effective amount of a thymoquinone derivative comprising a pair of substituted or unsubstituted six-membered carbon rings selected from the group consisting of phenyl and cyclohexadiene linked by a linker bonded to both of said six-membered rings claim 8 , at least one of said six-membered rings having a pair of oxygen-bearing substituents selected from the group consisting of carbonyl oxygens claim 8 , hydroxyls claim 8 , alkoxyls claim 8 , and halogenated derivatives ...

KETONE OR OXIME COMPOUND, AND HERBICIDE

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1): 2. The compound according to claim 1 , wherein R is —O-A.3. The compound according to claim 2 , wherein A is a hydrogen atom.4. The compound according to claim 2 , wherein q=3 and each Z is independently a halogen atom claim 2 , Calkyl claim 2 , or —OR.5. The compound according to claim 2 , wherein q=3 and a first Z represents a bromine claim 2 , a second Z represents methyl claim 2 , and a third Z represents —OCH.7. The compound according to claim 1 , wherein R is ═O.8. The compound according to claim 7 , wherein q=3 and each Z is independently a halogen atom claim 7 , Calkyl claim 7 , or —OR.9. The compound according to claim 7 , wherein q=3 and a first Z represents a bromine claim 7 , a second Z represents methyl claim 7 , and a third Z represents —OCH.11. The compound according to claim 7 , wherein q=3 and a first Z represents —OCH claim 7 , a second Z represents methyl claim 7 , and a third Z represents —OCH.13. The compound according to claim 7 , wherein q=3 and a first Z represents methyl claim 7 , a second Z represents methyl claim 7 , and a third Z represents —OCH. The present invention relates to a novel ketone or oxime compound or a salt thereof, and agricultural chemicals, in particular herbicides, containing the ketone or oxime compound or the salt thereof as an active component. The agricultural chemical in the present invention means an insecticide/acaricide, a nematicide, a herbicide, and a bactericide in agricultural and horticultural fields.For example, certain types of ketone or oxime compounds have been described in Patent Documents 1 to 4. The ketone or the oxime compound according to the present invention, however, has not been described at all.An object of the present invention is to provide a chemical substance that surely shows effect on various weeds in a low application amount of the chemical substance, has ...

COMPOUNDS FROM INVASIVE SALVINIAS AND METHODS OF USING THE SAME

In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same. 415.-. (canceled)16. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) the compound according to and/or a pharmaceutically acceptable salt thereof; and'}(b) an excipient.17. A method of treating cancer in a patient in need thereof ,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'comprising administering to the patient a pharmaceutical composition, the composition comprising an effective amount of a compound according to .'}18. The method of claim 17 , wherein the cancer is melanoma claim 17 , cervical cancer claim 17 , breast cancer claim 17 , ovarian cancer claim 17 , prostate cancer claim 17 , testicular cancer claim 17 , urothelial carcinoma claim 17 , bladder cancer claim 17 , non-small cell lung cancer claim 17 , small cell lung cancer claim 17 , sarcoma claim 17 , colorectal adenocarcinoma claim 17 , gastrointestinal stromal tumors claim 17 , gastroesophageal carcinoma claim 17 , colorectal cancer claim 17 , pancreatic cancer claim 17 , kidney cancer claim 17 , hepatocellular cancer claim 17 , malignant mesothelioma claim 17 , leukemia claim 17 , lymphoma claim 17 , myelodysplastic syndrome claim 17 , multiple myeloma claim 17 , transitional cell carcinoma claim 17 , neuroblastoma claim 17 , plasma cell neoplasms claim 17 , Wilm's tumor claim 17 , or hepatocellular carcinoma.1921.-. (canceled)22. The method of claim 17 , wherein said patient is further administered a distinct cancer therapy.2324.-. (canceled)25. The method of claim 17 , wherein the compound is isolated from a plant in the Salviniaceae family.26Salvinia. The method of claim 25 , wherein the compound is isolated from a plant in the genus.27Azolla. The method of claim 25 , wherein the compound is isolated from a plant in the genus.28. The method of claim ...

KETONE OR OXIME COMPOUND, AND HERBICIDE

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1): 2. The ketone compound or the salt thereof according to claim 1 , wherein A is a hydrogen atom claim 1 , Calkyl claim 1 , or —C(O)R;{'sup': '2', 'sub': '1-8', 'Ris Calkyl;'}{'sup': 6', '15', '16', '17', '1, 'sub': 1-6', '1-6', '3-8', '2-6', 'q1, 'Ris Calkyl, (C) alkyl arbitrarily substituted with R, Ccycloalkyl, Calkenyl, —C(═NOR)R, phenyl, phenyl substituted with (Z), or D1-32;'}{'sup': 8a', '16a', '17a, 'sub': '1-6', 'Ris a hydrogen atom, Calkyl, —C(O)OR, or —C(O)R;'}{'sup': '9a', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl;'}{'sup': 8b', '9b, 'Rand Rare hydrogen atoms;'}{'sup': 10', '1', '12, 'R, R, and Rare hydrogen atoms;'}{'sup': 15', '16, 'sub': '3-8', 'Ris a halogen atom, Ccycloalkyl, —OR, or phenyl;'}{'sup': 16', '16a', '17', '17a, 'sub': '1-6', 'R, R, R, and Rare each independently Calkyl;'}{'sup': '1', 'sub': '1-6', 'Xis halo (C) alkyl;'}{'sup': a', 'c', '45', '41', '3, 'sub': 1-6', '3-8', '2-6', '2-6', '2-6', 'q3, 'Zand Zare each independently a hydrogen atom, a halogen atom, Calkyl, Ccycloalkyl, Calkenyl, (C) alkenyl arbitrarily substituted with R, Calkynyl, —OR, phenyl, phenyl substituted with (Z), D1-7, D1-11, D1-22, D1-32, or D1-37;'}{'sup': '1', 'Zis a halogen atom;'}{'sup': '3', 'sub': 1-6', '1-6', '1-6', '1-6', '1-6, 'Zis a halogen atom, Calkyl, halo (C) alkyl, Calkoxy, halo (C) alkoxy, or Calkylthio;'}{'sup': 41', '45, 'sub': 1-6', '1-6, 'Ris Calkyl, (C) alkyl arbitrarily substituted with R, phenyl, D1-32, or D1-34;'}{'sup': '45', 'Ris a halogen atom, phenyl, or D1-34;'}g2, g3, and p are 0;q1 and q3 are integers of 1; andg4, m, and n are each independently an integer of 0 or 1.3. The ketone compound or the salt thereof according to claim 2 , whereinB is B-1-a;{'sup': 'a', 'sub': 1-6', '1-6, 'Zis a halogen atom, Calkyl, or Calkoxy; and'}{'sup': c', '45', '41', '3, 'sub': 1-6', '3-8', '2-6', '2-6', '2-6', 'q3, 'Zis ...

USAGE OF OBLONGIFOLIN C, A NATURAL COMPOUND FROM GARCINIA YUNNANENSIS HU, ON TREATING CANCER AS METASTASIS INHIBITOR AND AUTOPHAGIC FLUX INHIBITOR

Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising species such as Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux. 2. The composition according to claim 1 , wherein said compound comprising Oblongifolin C.3. The composition according to claim 1 , wherein said compound is isolated from a natural plant.4Garcinia. The composition according to claim 3 , wherein said natural plant comprising species.5GarciniaGarcinia yunnanesis. The composition according to claim 4 , wherein said species comprising Hu.6. The composition according to claim 1 , wherein the treated cancers comprising cervical cancers and esophageal cancers.7. The composition according to claim 1 , wherein the cancer treatment comprising inhibition of cancer metastasis and inhibition of autophagic flux.8. A use of the composition according to for manufacture of anticancer medicaments.9. The use according to claim 8 , wherein said composition is used as an autophagy inhibitor.10. A method of treating cancer using composition according to by administering said composition to a subject in need of such treatment.11. The method according to wherein said composition is administered by injection. This application claims the benefit of U.S. Provisional Patent Application No. 61/750,870 filed Jan. 10, 2013 and of Chinese Standard Patent Application Serial Number 201310101235.5 filed Mar. 26, 2013; both disclosures of which are incorporated herein by reference in their entirety.The present invention relates to a chemical entity isolated from natural sources for its therapeutic uses. More particularly, it relates to a compound that is naturally occurring in the plant of Hu and its biological activity of antitumor effects.Esophageal cancer is one of the most ...

5-substituted-5-hydroxy-5-aryl-3-oxo-pentanoate derivatives and their enantiopure forms

The present invention relates to novel tertiary alcohol derivatives substituted with aryl and trifluoromethyl, and optical isomers thereof. In addition, the present invention also relates to methods for the preparation and use as enantiomer recognition agent thereof. The present invention provides pharmaceutical composition and use as therapeutically active substance thereof.

Herbicidally Active 2-(Substituted-Phenyl)-Cyclopentane-1,3-Dione Compounds and Derivatives Thereof

The present invention relates to a compound of formula (I): wherein: Rand R, independently of each other, are hydrogen, fluorine or C-Calkyl; Ris hydrogen or methyl (preferably hydrogen); and the other substituents are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are thought to be suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof. 2. The compound as claimed in , wherein G is hydrogen; an agriculturally acceptable metal , or an agriculturally acceptable sulfonium or ammonium group; or G is —C(X)—Ror —C(X)—X—R , wherein X , R , X , Xand Rare as defined in .3. The compound as claimed in claim 1 , wherein X claim 1 , Xand Xare oxygen;{'sup': 'a', 'sub': 1', '10', '2', '6', '2', '6', '3', '6', '3', '6', '1', '4', '1', '4', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1, 'Ris C-Calkyl, C-Calkenyl, C-Calkynyl, C-Ccycloalkyl, C-Ccycloalkyl-methyl-, C-CalkoxyC-Calkyl, phenyl-methyl- (in which the phenyl is optionally substituted by 1 or 2 of, independently, C-Calkyl, Cfluoroalkyl, C-Calkoxy; Cfluoroalkoxy, fluorine, chlorine or cyano); phenyl or phenyl substituted by 1 or 2 of, independently, C-Calkyl, Cfluoroalkyl, C-Calkoxy, Cfluoroalkoxy, fluorine, chlorine or cyano; or monocyclic heteroaryl or monocyclic heteroaryl substituted by 1 or 2 of, independently, C-Calkyl, Cfluoroalkyl, C-Calkoxy, Cfluoroalkoxy, fluorine, chlorine or cyano;'}and{'sup': 'b', 'sub': 1', '10', '2', '5', '2', '2', '4', '2', '5', '2', '2', '4', '3', '6', '3', '6', '1', '4', '1', '4', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1', '1', '2', '1, 'Ris C-Calkyl, C-Calkenyl-CH—, C- ...

NOVEL COMPOUND, PREPARING METHOD THEREOF, AND USE THEREOF AS INHIBITORS OF HISTONE DEMETHYLASE

Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase. 2. The compound claim 1 , the isomer claim 1 , the derivative claim 1 , or the pharmaceutically acceptable salt of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently hydrogen claim 1 , a hydroxyl group claim 1 , or a substituted or unsubstituted Cto Calkly group.3. The compound claim 1 , the isomer claim 1 , the derivative claim 1 , or the pharmaceutically acceptable salt of claim 1 , wherein R claim 1 , R claim 1 , and Rare each independently a hydroxyl group.4. The compound claim 1 , the isomer claim 1 , the derivative claim 1 , or the pharmaceutically acceptable salt of claim 1 , wherein Ris a Cto Calkly group substituted with two or more halogen atoms.5. The compound claim 1 , the isomer claim 1 , the derivative claim 1 , or the pharmaceutically acceptable salt of claim 1 , wherein Ris a Cto Calkly group substituted with two halogen atoms.7StreptomycesStreptomyces. A genus SNC023 strain producing the compound of claim 1 , wherein the genus SNC023 strain is deposited under Korean Collection for Type Cultures (KCTC) Accession number KCTC12494BP.8StreptomycesCopris tripartitus.. The genus SNC023 strain of claim 7 , wherein the strain is separated or derived from an epidermis or body of a larva included in a brood ball of9. A method of producing the compound of claim 1 , the method comprising:{'i': Streptomyces', 'Streptomyces, 'culturing a genus SNC023 strain in a culturing medium, wherein the genus SNC023 strain is deposited under KCTC Accession number KCTC12494BP; and'}{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'separating the compound of from the culturing medium.'}10. The method of claim 1 , wherein the ...

COMPOSITIONS AND METHODS FOR THE MODULATION OF CYTOKINES

A method for modulating production of a cytokine, or molecule upregulated or down regulated by a cytokine, in a patient in need thereof, including administering to a patient a composition comprising at least one of a strontium-containing compound, a cysteine-based antioxidant, a polyhydroxyphenol and beta hydroxybutyric acid to the patient, whereby an amount of a cytokine in the patient is modulated. 1. A method for modulating production of a cytokine , or molecule upregulated or down regulated by a cytokine , comprising:administering to a patient in need thereof an effective amount of a composition comprising at least one compound selected from the group consisting of a strontium-containing compound, a cysteine-based antioxidant, a polyhydroxyphenol and beta hydroxybutyric acid, whereby an amount of a cytokine in the patient is modulated.2. The method of claim 1 , wherein the composition comprises a complex of a strontium-containing compound claim 1 , a cysteine-based antioxidant claim 1 , and at least one of polyhydroxyphenol and beta hydroxybutyric acid claim 1 , wherein the cysteine-based anti-oxidant and the at least one of polyhydroxyphenol and beta hydroxybutyric acid are optionally conjugated together by a cleavable bond.3. The method of claim 1 , wherein the cytokine is associated with inflammation.4. The method of claim 3 , wherein the cytokine or a molecule upregulated or down regulated by the cytokine is selected from the group consisting of Eotaxin-3 claim 3 , soluble tumor necrosis factor-alpha (sTNF-α) claim 3 , vascular cell adhesion molecule 1 (VCAM-1) claim 3 , interleukin-1 alpha (IL-1α) claim 3 , interferon gamma-induced protein 10 (IP-10) claim 3 , interferon-inducible T-cell alpha chemoattractant (I-TAC) claim 3 , interleukin-8 (IL-8) claim 3 , serum amyloid A protein (SAA) claim 3 , monocyte chemoattractant protein-1 (MCP-1) claim 3 , prostaglandin E2 (sPGE2) claim 3 , intercellular adhesion molecule 1 (ICAM-1) claim 3 , monokine induced by ...

Inhibitors of beta-secretase

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

Cyclohexanone compounds and herbicides comprising the same

The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH 2 , O, S, S(O) or S(O) 2 ; R 1 represents a hydrogen atom or a methyl group; R 2 and R 3 represents a hydrogen atom, a C 1-6 alkyl group and the like; R 4 represents a C 6-10 aryl group or a five- to six-membered heteroaryl group; G represents a hydrogen atom and the like; Z represents a halogen atom, a cyano group, a nitro group, a phenyl group, a C 1-6 alkyl group and the like; is useful as an active ingredient for herbicides.

Substituted Tropolone Derivatives and Methods of Use

The compositions and methods described herein relate generally to substituted tropolone derivatives, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.

Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

Inhibitors of beta-secretase

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. 113-. (canceled)15. The method of claim 14 , wherein the BACE1 mediated disorder or disease is selected from the group consisting of neurodegenerative disorder claim 14 , cognitive decline claim 14 , cognitive impairment claim 14 , dementia and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.16. The method of claim 15 , wherein the disorder or disease is selected from the group consisting of Alzheimer's disease claim 15 , Trisomy 21 (Down Syndrome) claim 15 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D) claim 15 , senile dementia claim 15 , cerebral amyloid angiopathy claim 15 , degenerative dementia claim 15 , dementias of mixed vascular and degenerative origin claim 15 , dementia associated with Parkinson's disease claim 15 , dementia associated with progressive supranuclear palsy claim 15 , dementia associated with cortical basal degeneration claim 15 , diffuse Lewy body type of Alzheimer's disease claim 15 , dry age related macular degeneration (AMD) claim 15 , and glaucoma.1718-. (canceled) This application is a continuation of U.S. application Ser. No. 14/011,183, filed Aug. 27, 2013, which claims the benefit of U.S. Provisional Application Ser. No. 61/693,512, filed Aug. 27, 2012, U.S. Provisional Application Ser. No. 61/788,839, filed Mar. 15, 2013, and U.S. Provisional Application Ser. No. 61/816,458, filed Apr. 26, 2013. The entire teachings of each of the above applications are incorporated herein by reference.The instant application contains a Sequence Listing which ...

ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX

Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound. 2. The compound of claim 1 , wherein n is 5 claim 1 , 7 claim 1 , or 9.12. A pharmaceutical composition comprising a compound of claim 1 , or a salt thereof claim 1 , and a pharmaceutically acceptable excipient.13. A method for treating a clinical condition associated with signaling mediated by TLR1/2 comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of .14. The method of claim 13 , wherein the clinical condition is a chronic inflammatory disease or an acute inflammatory disease.15. The method of claim 14 , wherein the chronic inflammatory disease or the acute inflammatory disease is atopic dermatitis claim 14 , psoriasis claim 14 , acne vulgaris or sepsis.16. The method of claim 14 , wherein the chronic inflammatory disease or the acute inflammatory disease is caused by human cytomegalovirus claim 14 , lymphocytic choriomeningitis virus claim 14 , or herpes simplex virus 1.17. The method of claim 13 , wherein the clinical condition is pulmonary tumor metastasis. This invention was made with government support under grant numbers DA026950, DA025740 and NS067425 awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.Embodiments herein report compositions, methods, and uses for treating Toll-like receptor 1/2 complex (TLR1/2) related immune disorders. Some embodiments of the present invention provide small molecules capable of ...

1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hapatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media. 3. The 1 claim 1 ,3-Dioxoindene derivatives as set forth in claim 1 , pharmaceutically-acceptable salt thereof or optical isomer thereof claim 1 , wherein claim 1 , A claim 1 , A claim 1 , Aand Aare claim 1 , either independently or optionally claim 1 , any one selected from a group consisting of —H claim 1 , halogen and —NRR;{'sup': 1', '2', '1', '2, 'G is —OH, —NR(C═O)Ror —NR(C═O)OR;'}{'sup': 1', '2', '3', '4', '1', '2, 'sub': 1', '10, 'D, D, Dand Dare, either independently or optionally, any one selected from a group consisting of halogen, C˜Cstraight- or side-chain alkyl and —NR(C═O)R;'}{'sup': 1', '1', '1', '1', '2, 'E is —H, —OH, —OR, —O(C═O)R, —O(C═O)ORor —O(C═O)NRR;'}{'sup': 1', '2', '3, 'sub': 1', '8', '1', '4', '6', '10, 'R, Rand Rare, each independently, hydrogen, nonsubstituted or phenyl-substituted C˜Cstraight- or side-chain alkyl, nonsubstituted or phenyl-substituted C˜Cstraight- or side-chain alkenyl or C˜Caryl;'}X and Y are oxygen;{'sup': 1', '2', '3, 'Z, Zand Zare carbon;'}n is integer between 1˜3; and{'img': {'@id': 'CUSTOM- ...

HERBICIDALLY ACTIVE CYCLIC DIONE COMPOUNDS, OR DERIVATIVES THEREFOR, SUBSTITUTED BY A PHENYL WHICH HAS AN ALKYNYL-CONTAINING SUBSTITUENT

The present invention relates to a compound of formula (I), wherein: X is methyl or chlorine; Ris methyl or chlorine; Ris hydrogen, methyl, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, fluorine, chlorine, bromine, C-Calkoxy, C-C-fluoroalkoxy, C-Calkoxy-C-Calkoxy- or Cfluoroalkoxy-C-Calkoxy-; and Y is O, S, S(O), S(O), N(C-Calkyl), N(C-Calkoxy), C(O), CRRor —CRRCRR—; and G, R, R, Rand Rare as defined herein; wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof. 2. The compound as claimed in claim 1 , wherein G is hydrogen; an agriculturally acceptable metal claim 1 , or an agriculturally acceptable sulfonium or ammonium group; or G is —C(X)—Ror —C(X)—X—R claim 1 , wherein X claim 1 , R claim 1 , X claim 1 , Xand Rare as defined herein.3. (canceled)4. (canceled)5. The compound as claimed in claim 1 , wherein X is methyl.6. The compound as claimed in claim 1 , wherein X is chlorine.7. The compound as claimed in claim 1 , wherein Ris methyl.8. The compound as claimed in claim 1 , wherein Ris chlorine.9. The compound as claimed in claim 1 , wherein X is methyl claim 1 , and Ris methyl.10. The compound as claimed in claim 1 , wherein X is methyl claim 1 , and Ris chlorine.11. (canceled)12. (canceled)13. (canceled)14. The compound as claimed in claim 1 , wherein Ris methyl or methoxy.15. (canceled)16. (canceled)17. (canceled)18. The compound as claimed in claim 1 , wherein:{'sup': 1', '2, 'Ris chlorine, and Ris methoxy.'}19. (canceled)20. The compound as claimed in claim 1 , wherein R claim 1 , R claim 1 , Rand R claim 1 , independently of each other claim 1 , are hydrogen or C-Calkyl;{'sup': 4 ...

Clostrubins

The present invention relates to a bioactive compound according to general formula (I); to a pharmaceutical composition comprising one or more of the compound(s); and to the use of the compound(s) as an antibiotic, cytotoxic and/or anti—proliferative agent.

KETONE OR OXIME COMPOUND, AND HERBICIDE

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1): 3. The ketone compound or the salt thereof according to claim 2 , wherein Q is an oxygen atom.4. The oxime compound or a salt thereof according to claim 2 , wherein Q is ═NOR.5. The ketone compound or the salt thereof according to claim 3 , wherein A is a hydrogen atom claim 3 , Calkyl claim 3 , or —C(O)R;{'sup': '2', 'sub': '1-s', 'Ris Calkyl;'}{'sup': 6', '15', '16', '17', '1, 'sub': 1-6', '1-6', '3-8', '2-6', 'q1, 'Ris Calkyl, (C) alkyl arbitrarily substituted with R, Ccycloalkyl, Calkenyl, —C(═NOR)R, phenyl, phenyl substituted with (Z), or D1-32;'}{'sup': 8a', '16a', '17a, 'sub': '1-6', 'Ris a hydrogen atom, Calkyl, —C(O)OR, or —C(O)R;'}{'sup': '9a', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl;'}{'sup': 8b', '9b, 'Rand Rare hydrogen atoms;'}{'sup': 10', '11', '12, 'R, R, and Rare hydrogen atoms;'}{'sup': 15', '16, 'sub': '3-8', 'Ris a halogen atom, Ccycloalkyl, —OR, or phenyl;'}{'sup': 16', '16a', '17', '17a, 'sub': '1-6', 'R, R, R, and Rare each independently Calkyl;'}{'sup': '1', 'sub': '1-6', 'Xis halo (C) alkyl;'}{'sup': a', 'c', 'e', '45', '41', '3, 'sub': 1-6', '3-8', '2-6', '2-6', '2-6', 'q3, 'Z, Zand Zare each independently a hydrogen atom, a halogen atom, Calkyl, Ccycloalkyl, Calkenyl, (C) alkenyl arbitrarily substituted with R, Calkynyl, —OR, phenyl, phenyl substituted with (Z), D1-7, D1-11, D1-22, D1-32, or D1-37;'}{'sup': '1', 'Zis a halogen atom;'}{'sup': '3', 'sub': 1-6', '1-6', '1-6', '1-6', '1-6, 'Zis a halogen atom, Calkyl, halo (C) alkyl, Calkoxy, halo (C) alkoxy, or Calkylthio;'}{'sup': 41', '45, 'sub': 1-6', '1-6, 'Ris Calkyl, (C) alkyl arbitrarily substituted with R, phenyl, D1-32, or D1-34;'}{'sup': '45', 'Ris a halogen atom, phenyl, or D1-34;'}g2, g3, and p are 0;q1 and q3 are integers of 1; andg4, m, and n are each independently an integer of 0 or 1.6. The ketone compound or the salt thereof according to ...

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. 1. A compound having the following structure:or a pharmaceutically acceptable salt thereof. This application is a continuation of U.S. patent application Ser. No. 15/383,287, filed on Dec. 19, 2016, which is a continuation of U.S. patent application Ser. No. 14/613,550, filed on Feb. 4, 2015, now U.S. Pat. No. 9,526,727, which is a continuation of U.S. patent application Ser. No. 13/784,032, filed Mar. 4, 2013, now U.S. Pat. No. 8,981,112, which, in turn, claims the benefit of U.S. Provisional Application Ser. No. 61/606,786, filed Mar. 5, 2012; the entire contents of each of the aforementioned applications are incorporated herein by reference.The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 4, 2013, is named 15161953.txt and is 718 bytes in size.The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid deposits or neurofibrillary tangles.β-Amyloid (also referred to herein as “Abeta” or “Aβ”) deposits and neurofibrillary tangles are two major pathologic characterizations associated with Alzheimer's disease (AD), including the genetically linked early onset ...

Fluorene compounds

New fluorene derivatives and new methods for forming fluorene derivatives are disclosed. Examples include processes for preparing tert-butyl substituted fluorenes, 1-methyl fluorene, and 4-methyl fluorene.

Vinly-substituted bridged metallocenes

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Process of polymerizing olefins using diphenylsilyl or dimethyl tin bridged 1-methyl fluorenyl metallocenes

Group IVB metal metallocenes of bis(1-methyl fluorenyl) diphenyl silane and bis(1-methyl fluorenyl) dimethyl tin are disclosed, plus their use in the production of polyolefins, including isotactic polypropylene.

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the β- position and a halogen atom in the α-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the α-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Organometallic fluorenyl compounds and use thereof in an alpha-olefin polymerization process

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

C2-phenyl-substituted cyclic keto-enols used as pesticides and herbicides

The present invention relates to novel C 2 -phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y, Z and CKE are as defined in the description, to processes for their preparation and to their use as pesticides and herbicides.

4-phenyl-pyrane-3,5-diones, 4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones as novel herbicides

Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.

Herbicidally active bicyclic 1,3-dione compounds

Bicyclic dione compounds of formule (I), and derivatives thereof, which are suitable for use as herbicides.

Organometallic fluorenyl compounds, preparation and use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Cyclopentadiene type compounds and method for making

New fluorenyl silane compounds and method for their production are disclosed. The fluorenyl compounds have the formula ##STR1## wherein Z is a substituted or unsubstituted fluorenyl radical and Z' is a substituted or unsubstituted cyclopentadienyl-type radical or a halogen.

Olefin polymerization using silyl-bridged metallocenes

Fluorenyl-containing silyl bridged metallocenes, the process of using such metallocenes to polymerize olefins, and the resulting unusual syndiotactic polypropylene are disclosed.

Organometallic fluorenyl compounds, preparation, and use

Bridged fluorenyl-containing metallocenes of metals of Groups 4-6 and their use in forming homopolymers of alpha olefins or polymers of ethylene and optionally minor amounts of alpha olefins, wherein in each case at least one of the cyclic groups of the bridged ligand is a fluorenyl and the other is selected from indenyl, tetrahydroindenyl, fluorenyl, and in the case of the polymerization of ethylene optionally cyclopentadienyl.

Bis fluorenyl metallocenes and use thereof

Group IVB metal metallocenes of bis(1-methyl fluorenyl) diphenyl silane and bis(1-methyl fluorenyl) dimethyl tin are disclosed, plus their use in the production of polyolefins, including isotactic polypropylene.

Organometallic fluorenyl compounds, preparations, and use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Organometallic fluorenyl compounds, preparation, and use

Bridged and unbridged fluorenyl-containing metallocenes of the formula R″ x (FlR n )(CpR m )MQ k wherein Fl is a fluorenyl radical, Cp is a cyclopentadienyl, indenyl, tetrahydroindenyl, or fluorenyl radical, each R is an organo radical, R″ is a structural bridge linking (FlR n ) and (CpR m ), M is a metal selected from the group consisting of IVB, VB, and VIB metals, each Q is selected from the group consisting of hydrocarbyl or hydrocarbyloxy radicals and halogen, x is 1 or 0, k is an integer sufficient to fill out the remaining valences of M, n is in the range of 0 to 7, and m is 0 to 7, further characterized by the fact that if (CpR m ) is unsubstituted fluorenyl and metallocene is an unbridged metallocene, then n is 1 to 7 and if R″ is 1,1-dimethylmethylene and (CpR m ) is unsubstituted cyclopentadienyl or 3-methylcyclopentadienyl, then n is 1 to 7.

Organometallic Fluorenyl Compounds, Preparations, and Use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Syndiotactic polypropylene prepared using silyl bridged metallocenes

Fluorenyl-containing silyl bridged metallocenes, the process of using such metallocenes to polymerize olefins, and the resulting unusual syndiotactic polypropylene are disclosed.

Organometallic fluorenyl compounds and use thereof in olefin polymerization

Unbridged fluorenyl containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Metallocenes and processes therefor and therewith

Cyclopentadiene type compounds and method for making

Processes are disclosed for preparing compounds of the formula Z-R-Z where each Z can be selected from cyclopentadienyl type radicals such as substituted or unsubstituted cyclopentadienyl, indenyl, fluorenyl or tetrahydroindenyl or where one Z is Cl, Br, or I by reacting specific Z precursors with a dihaloalkylene compound. Also new cyclopentadienyl-type compounds are disclosed.

New tert.-butyl-fluorene cpds. - useful as antiviral and fluorenyl-metallocene intermediates and as polyamide and polyurea monomers

1-, 2- or 4-tert.butyl-fluorenes (I) are new. USE - (I) are intermediates for antiviral drugs and fluorenylmetallocene catalysts as well as monomers for the mfr. of polyamides and polyureas. In an example, AlMe3 (4.6 ml.) was added to a suspension of 1-carboxyfluorene (III) (2 g.) in toluene and the mixt. was refluxed, cooled and added to dil. HCl. The organic phase was washed, dried and evaporated to give after extn. (pentane), silica gel purificn. and evapn., 1-tert.butyl-fluorene (I) in quantitative yield.

Cyclopentadiene type compounds and method for making

Processes are disclosed for preparing compounds of the formula Z--R--Z where each Z can be selected from cyclopentadienyl type radicals such as substituted or unsubstituted cyclopentadienyl, indenyl, fluorenyl or tetrahydroindenyl or where one Z is Cl, Br, or I by reacting specific Z precursors with a dihaloalkylene compound. Also new cyclopentadienyl-type compounds are disclosed.

Method for producing fluorenyl-containing metallocene

Organometallic fluorenyl compounds, preparation, and use

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Cyclopetadiene type compounds and method for making

Processes are disclosed for preparing compounds of the formula Z-R-Z where each Z can be selected from cyclopentadienyl type radicals such as substituted or unsubstituted cyclopentadienyl, indenyl, fluorenyl or tetrahydroindenyl or where one Z is Cl, Br, or I by reacting specific Z precursors with a dihaloalkylene compound. Also new cyclopentadienyl-type compounds are disclosed.

Metallocenes and processes therefor and therewith

A method is provided for forming a supported cyclopentadiene-type compound comprising contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having surface hydroxyl group. Also there is provided a method of preparing a supported metallocene comprising reacting the supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. There is also provided a process for producing bridged cyclopentadiene-type ligands having a bridge having branch that has a terminal vinyl group. Also metallocenes of these ligands are provided. Still further there is provided a process for producing bridged cyclopentadiene-type ligands having a bridge having a branch that has a terminal active halogen. The resulting new ligands and supported metallocenes produced therefrom are also provided. There is further provided supported metallocene catalysts wherein at least two metallocenes of differing effectiveness are both bonded to an inorganic support having surface hydroxy groups. Olefin polymerization employing the inventive bridged supported metallocenes is also provided, as well the resulting polymer products.

Metallocenes and processes therefor and therewith

METALOCENOS AND PROCEDURES FOR THEIR PREPARATION AND USE.

SE SUMINISTRA UN METODO PARA FORMAR UN COMPUESTO DE TIPO DEL CICLOPENTADIENO SOPORTADO QUE COMPRENDE LA PUESTA EN CONTACTO DE UN COMPUESTO DEL TIPO DE CICLOPENTADIENO QUE COMPRENDA UN HALOGENO ACTIVO CON UN SOPORTE INORGANICO QUE TENGA UN GRUPO DE HIDROXIL SUPERFICIAL. TAMBIEN SE SUMINISTRA UN METODO PARA PREPARAR UN METALOCENO SOPORTADO QUE COMPRENDE LA REACCION DEL COMPUESTO DEL TIPO DEL CICLOPENTADIENO SOPORTADO CON UN COMPUESTO DE UN METAL DE TRANSICION BAJO CONDICIONES ADECUADAS. TAMBIEN SE SUMINISTRA UN PROCESO PARA PRODUCIR LIGANTES DEL TIPO DEL CICLOPENTADIENO PUENTEADO QUE TENGAN UN PUENTE QUE TENGA UNA RAMA QUE SEA UN GRUPO DE VINIL TERMINAL. TAMBIEN SE SUMINISTRAN METALOCENOS DE ESTOS LIGANTES. AUN MAS SE SUMINISTRA UN PROCESO PARA PRODUCIR LIGANTES DEL CICLOPENTADIENO PUENTEADO QUE TENGA UN PUENTE QUE TENGA UNA RAMA QUE TENGA UN HALOGENO ACTIVO TERMINAL. TAMBIEN SE SUMINISTRAN LOS NUEVOS LIGANTES RESULTANTES Y NUEVOS METALOCENOS SOPORTADOS PRODUCIDOS MEDIANTE ESTE METODO. ADEMASSE SUMINISTRAN CATALIZADORES DE METALOCENO SOPORTADO EN LOS QUE AL MENOS DOS METALOCENOS DE EFECTIVIDAD DIFERENTE SE ENCUENTRAN UNIDOS ENTRE SI A UN SOPORTE INORGANICO QUE TENGA GRUPOS DE HIDROXIDO SUPERFICIAL. TAMBIEN SE SUMINISTRA UNA POLIMERIZACION DE OLEFINA QUE EMPLEA LOS METALOCENOS SOPORTADOS, PUENTEADOS DE LA INVENCION ASI COMO EL PRODUCTO DE POLIMERO RESULTANTE. A METHOD IS PROVIDED TO FORM A COMPOSITE TYPE OF THE SUPPORTED CYCLOPENTADIENE THAT INCLUDES THE SETTING IN CONTACT OF A CYCLOPENTADIEN TYPE COMPOSITE THAT INCLUDES AN ACTIVE HALOGEN WITH AN INorganic SUPPORT THAT HAS A SUPERX GROUP. A METHOD IS ALSO SUPPLIED TO PREPARE A SUPPORTED METALOCENE THAT UNDERSTANDS THE REACTION OF THE CYCLOPENTADIEN TYPE COMPOSITE SUPPORTED WITH A COMPOSITE OF A TRANSITION METAL UNDER ADEQUATE CONDITIONS. A PROCESS IS ALSO PROVIDED TO PRODUCE BINDERS OF THE TYPE OF BRIDGED CYCLOPENTADIEN THAT HAVE A BRIDGE THAT HAS A BRANCH THAT IS A TERMINAL VINYL GROUP. METALOCENOS OF THESE BINDERS ...

Metalloseeneja ja siihen liittyviä menetelmiä

Metallocenes and preparation methods thereof

활성 할로겐을 함유한 시클로펜타디엔-형 화합물을 표면 히드록실 기를 갖는 무기 지지체와 접촉시키는 것으로 구성되는 지지된 시클로펜타디엔-형 화합물 형성 방법이 제공된다. 또한 지지된 시클로펜타디엔-형 화합물을 적합한 조건하에 전이 금속 화합물과 반응시키는 것으로 구성되는 지지된 메탈로센 제조 방법이 제공된다. 또한 말단 비닐기를 갖는 분지를 갖는 가교를 갖는 가교된 시클로펜타디엔-형 리간드 생성 방법이 제공된다. 또한 상기 리단드의 메탈로센이 제공된다. 또한 부가로 말단 활성 할로겐을 갖는 분지를 갖는 가교를 갖는 가교된 시클로펜타디엔-형 리간드 생성방법이 제공된다. 결과얻어진 신규 리간드 및 그로부터 생성된 지지된 메탈로센이 또한 제공된다. 부가로 다른 효과를 갖는 적어도 두개의 메탈로센이 모두 표면 히드록시 기를 갖는 무기 지지체에 결합된 지지된 메탈로센 촉매가 제공된다. 발명의 가교된 지지된 메탈로센을 사용하는 올레핀 중합이 결과 얻어진 중합 생성물과 더불어 또한 제공된다. A method of forming a supported cyclopentadiene-type compound is provided which consists of contacting a cyclopentadiene-type compound containing an active halogen with an inorganic support having a surface hydroxyl group. Also provided is a method for preparing a supported metallocene, consisting of reacting a supported cyclopentadiene-type compound with a transition metal compound under suitable conditions. Also provided is a method of producing a crosslinked cyclopentadiene-type ligand having a crosslink having branches with terminal vinyl groups. Also provided are metallocenes of the reddide. Also provided is a method of producing a crosslinked cyclopentadiene-type ligand having a crosslink having branches with terminally active halogens. The resulting novel ligands and the supported metallocenes produced therefrom are also provided. In addition, a supported metallocene catalyst is provided in which at least two metallocenes with different effects are both bound to an inorganic support having surface hydroxy groups. Olefin polymerization using the crosslinked supported metallocene of the invention is also provided along with the resulting polymerization product.

Vinyl-substituted bridged metallocenes

Metallocenes, their production and use

Metallocener og fremgangsmåte til deres fremstilling og bruk

Det er tilveiebragt en fremgangsmåte til å danne en un- derstøttet syklopentadien-type forbindelse som omfatter å bringe en syklopentadien-type forbindelse som inneholder et aktivt halogen i berøring med en uorganisk understøt- telse som har overflatehydroksylgruppe. Det er også tilveiebragt en framgangsmåte til å fremstille et understøt- tet metallocen som omfatter å omsette den understøttede syklopentadien-type forbindelse med en overgangsmetall- forbindelse under egnede betingelser. Det er også tilveie- bragt en fremgangsmåte til å fremstille brosyklopentadien- type ligander som har en bro som har en gren som har en avsluttende vinylgruppe. Også metallocener av disse ligander er tilveiebragt. Enda ytterligere er det tilveiebragt en fremgangsmåte for å fremstille brosyklopentadien-type ligander som har en bro som har en gren som har et avsluttende aktivt halogen. De resulterende nye ligander og understøttede metallocener produsert derav er også tilveiebragt. Det er videre tilveiebragt understøttede metallocenkatalysatorer hvor minst to metallocener av forskjellig effektivitet begge er bundet til en uorganisk understøttelse som har overflatehydroksygrupper. Alken- polymerisasjon som benytter de understøttede brometal- locener er også tilveiebragt såvel som de resulterende polymerprodukter.

Processos para preparação de compostos do tipo ciclopentadieno suportado e ciclopentadienila com ponte, processo para preparação de um metaloceno e processo para polimerização de uma olefina

[UNK]

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the β-position and a halogen atom in the α-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the α-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the β-position and a halogen atom in the α-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the α-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the β-position and a halogen atom in the α-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the α-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the β-position and a halogen atom in the α-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the α-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Organometallic fluorenyl compounds, preparation, and use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Organometallic fluorenyl compounds, preparation, and use

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

COSMETIC LIGHT PROTECTION AGENTS FOR THE UV-A AREA

Patent FR2430938B1

NOVEL 3-BENZYLIDENE CAMPHOR DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PROTECTIVE AGENTS AGAINST UV RAYS AND AS MEDICAMENTS

PHARMACEUTICAL COMPOSITIONS CONTAINING CAMPHO-METHYLIDENE CINNAMIC ACID DERIVATIVES

antioxidants

Die vorliegende Erfindung betrifft die Verwendung von Verbindungen der Formel I X-Ar-Y, wobei X und Y jeweils unabhängig voneinander ausgewählt sind aus den Resten H, C<SUB>1-8</SUB>-Alkyl und den Resten gemäß den Formeln Ia, Ib oder Ic, $F1 mit in der Beschreibung definierten sonstigen Resten, als Antioxidans, entsprechende neue Verbindungen und Zubereitungen sowie entsprechende Herstellverfahren für Verbindungen und Zubereitungen. The present invention relates to the use of compounds of the formula I X-Ar-Y, where X and Y are each independently selected from the radicals H, C <SUB> 1-8 </SUB> alkyl and the radicals according to the formulas Ia, Ib or Ic, $ F1 with other radicals defined in the description, as an antioxidant, corresponding new compounds and preparations and corresponding production processes for compounds and preparations.

Cosmetic light-stabilising agent for the UV-A region

Metallocener og fremgangsmåte til polymerisering av olefin

Benzofluorenyl-inneholdende metallocener beskrives sammen med fremgangsmåter for å lage disse metal- locenene. Det er også beskrevet fremgangsmåter for å anvende metallocenene som polymerisasjonskatalysa- torer. l tillegg beskrives polymerene som oppnås fra slike polymerisasjoner.

Fulbene, metallocene catalyst and method for producing the same, and method for producing polyolefin copolymer using the same

Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same

Organometallic fluorenyl compounds, preparation, and use

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Cyclopetadiene type compounds and method for making

Silyl bridged metallocenes and use thereof

Fluorenyl-containing silyl bridged metallocenes, the process of using such metallocenes to polymerize olefins, and the resulting unusual syndiotactic polypropylene are disclosed.

Benzofluorenylmetallocene and method of polymerization of olefins

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Organometallic fluorenyl compounds, preparation, and use

Use of organometallic flurorenyl compounds.

Fluorenyl-inneholdende metallocener, fremgangsmåte for fremstilling derav og fremgangsmåte for polymerisering av olefiner ved anvendelse av metallocenene

Fluorenyl-inneholdende metallocener er beskrevet sammen med fremgangsmåter for å lage metallo- cenene. Det er også beskrevet fremgangsmåter for anvendelse av metallocenene som polymerisasjons- katalysatorer. I tillegg beskrives polymerer som oppnås fra slike polymerisasjoner.

USE OF FLUORENYL ORGANOMETAL COMPOUNDS.

SE PRESENTAN METALOCENOS QUE CONTIENEN FLUORENILO JUNTO CON LOS METODOS PARA LA PRODUCCION DE LOS METALOCENOS. TAMBIEN SE PRESENTAN LOS METODOS PARA EL USO DE LOS METALOCENOS COMO CATALIZADORES DE POLIMERIZACION. ADEMAS, SE PRESENTAN LOS POLIMEROS RESULTANTES DE TALES POLIMERIZACIONES. METALOCENS ARE PRESENTED THAT CONTAIN FLUORENYL TOGETHER WITH METHODS FOR METALOCENE PRODUCTION. METHODS FOR THE USE OF METALOCENES AS POLYMERIZATION CATALYSTS ARE ALSO PRESENTED. IN ADDITION, THE RESULTING POLYMERS OF SUCH POLYMERIZATIONS ARE PRESENTED.

METALLOCENE WITH SILILE BRIDGE AND ITS USE.

SE PRESENTAN METALOCENOS PUENTEADOS DE SILIL QUE CONTIENEN FLUORENIL, UN PROCESO PARA LA UTILIZACION DE TALES METALOCENOS PARA POLIMERIZAR OLEFINAS, Y EL POLIPROPILENO SINDIOTACTICO INUSUAL RESULTANTE. INTRODUCING FLUORENIL-CONTAINED SILIL BRIDGED METALLOCENES, A PROCESS FOR THE USE OF SUCH METALLOCENES TO POLYMERIZE OLEFINS, AND THE RESULTING UNUSUAL SYNOTOTACTIC POLYPROPYLENE.

Organometallic fluorenyl compounds, preparation, and use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Organometallic Fluorenyl Compounds, Preparation, and Use

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Syndiotactic polypropylene prepared using silyl bridged metallocenes

PURPOSE: Provided is a syndiotactic polypropylene polymer having unexpectedly low density and low stiffness and tensile properties for the observed syndiotacticity thereof. CONSTITUTION: The syndiotactic polypropylene polymer is a homopolymer of propylene. The propylene homopolymer has a syndiotacticity of 50% or more and an isotacticity content of 5.11 to 6.74, when measured by NMR. Further, the propylene homopolymer includes 50 wt% or more of xylene-soluble materials and has a molecular weight of 45,000 to 66,000. In a variant, the propylene homopolymer has a syndiotacticity of 70% or more, when measured by NMR, and an average length of syndiotactic blocks of less than 10.

Silyl bridged metallocenes and use thereof

Fluorenyl-containing silyl bridged metallocenes, the process of using such metallocenes to polymerize olefins, and the resulting unusual syndiotactic polypropylene are disclosed.

Cyclopentadiene type compounds and method for making

Processes are disclosed for preparing compounds of the formula Z--R--Z where each Z can be selected from cyclopentadienyl type radicals such as substituted or unsubstituted cyclopentadienyl, indenyl, fluorenyl or tetrahydroindenyl or where one Z is Cl, Br, or I by reacting specific Z precursors with a dihaloalkylene compound. Also new cyclopentadienyl-type compounds are disclosed.

有机金属芴基化合物及使用该化合物聚合烯烃的方法

含有苯并芴基的金属茂和制备该金属茂的方法一起公开。还公开了用该金属茂作聚合催化剂的方法。另外，公开了由该聚合得到的聚合物。

Organometallic fluorenyl compounds, preparation, and use

Benzofluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.

Organometallic fluorenyl compounds, preparation, and use

Fluorenyl-containing metallocenes are disclosed along with methods for making the metallocenes. Also disclosed are methods for using the metallocenes as polymerization catalysts. In addition, polymers resulting from such polymerizations are disclosed.